Sat, Dec 27, 2014, 9:37 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Intercept Pharmaceuticals, Inc. Message Board

  • roxettewish roxettewish Jan 11, 2014 8:38 AM Flag

    For those who didn't read the WSJ article the chlorestoral thing is not significant it was known before and is common in NASH

     

    and is common in NASH

    In its written statement Friday to The Wall Street Journal, the NIH confirmed that treatment with OCA in the study was stopped early because an interim analysis showed the drug had a "significant beneficial effect on liver damage" in patients with nonalcoholic steatohepatitis, or NASH. The disease, estimated to affect 2% to 5% of Americans, involves fat accumulation in the liver that can cause inflammation and lead to more serious liver conditions.
    The NIH described the lipid abnormalities as "increased total cholesterol," with increased low-density lipoprotein cholesterol, also known as LDL or "bad cholesterol," and decreased high-density lipoprotein, or HDL, also known as "good cholesterol."
    Dr. Pruzanski said previous studies have shown that OCA can raise lipid levels, and that the company is studying these effects. He said the results of some of this research are publicly available on Intercept's website. "It's very public that our drug, among other things, impacts lipid metabolism," he said.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Ummmm.......you seem to have purposely left out the fact that the increased bad cholestrol was seen vs. the placebo!!!!! In other words, you are manipulating the truth. This is a very safe bet to SHORT at these levels. ICPT gets pummeled Monday. This thing is WAY over-valued and may NEVER make it to market.

      • 2 Replies to peteharmisan
      • you cannot be serious.

        increasing bad cholestrol vs liver transplant at costs of hundreds thousands dollars JUST TO SURVIVE! and the cirrhosis drug is so successful in treatment that trials WERE SUSPENDED!!

        expect numerous pharma companies to bid here and merril believes 800 sounds about right.
        let the bidding wars begin.

      • jonathan.odom@rocketmail.com jonathan.odom Jan 11, 2014 11:17 AM Flag

        Slightly modifying the diet would overcome the modest increase in LDL. Do you know how many other things in life including coffee, chocolate, milk...meat...eggs...stress... and many other drugs on the market that are billion dollar sellers have the same effect. Lack of scientific knowledge for shorts is pitiful. This is conservatively a $760 company. With only 20M shares outstanding. You have no idea how impactful a product like this is.

    • People with that liver disease dont produce enough of their own bile acid to have normal liver function. So they take additional bile acid in tablet form. In comes ICPTs OCA "drug". However, its a derivative of bile acid. Why? To justify a legal patent and call it "synthetic". The fact is, an exact copy of natural human bile acid would of worked but you cant patent something that already exist naturally in the body. The derivative form is a red herring.

      Sentiment: Strong Buy

 
ICPT
155.72+4.23(+2.79%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.